What kind of drug does Pimitespib belong to and what are its characteristics?

Pimitespib is an oral, small-molecule heat shock protein 90 (HSP90) inhibitor that is mainly used to treat specific types of malignant tumors. HSP90 is a molecular chaperone protein that is highly expressed in tumor cells and maintains the stability and function of a variety of oncogenic proteins. By inhibiting HSP90, pimetibi can promote the degradation of multiple tumor-related proteins, thereby inhibiting the growth and proliferation of cancer cells. This mechanism makes it a representative of multi-target anti-cancer drugs.

Pimetibi was first developed in Japan and has been approved in Japan for the treatment of patients with refractory gastric cancer, especially those who have failed standard chemotherapy regimens. Clinical studies have shown that pimetibi can delay disease progression, improve patients' progression-free survival (PFS), and bring about stable disease control in some cases. In addition, as an oral drug, it is more convenient than intravenous drugs and is more suitable for long-term maintenance treatment.

Compared with other targeted drugs, pimetibib has the characteristics of multi-target action and is not limited to a specific gene mutation. This means it may have therapeutic potential against multiple types of solid tumors, including lung, breast, colorectal, and more. However, it should be noted that due to its broad mechanism of action, it may also cause a certain degree of adverse reactions, such as diarrhea, fatigue, leukopenia, etc. Patients need to closely monitor their physical reactions when using it.

At present, pimetibib has not been approved for marketing in mainland China, so it is not available through formal channels and is not included in the medical insurance catalog. For patients in need of treatment, the drug can only be obtained through international drug purchasing or overseas medical treatment. In the future, if pimetibi can be approved for marketing in China and entered into medical insurance, it will provide new treatment options for more patients with advanced cancer.

Reference materials:https://www.mt-pharma.co.jp/e/company/rd/pipe/